In spite of a major public health burden with increasing prevalence, current osteoarthritis
(OA) management is largely palliative with an unmet need for effective treatment. Both …

While acute inflammation is a natural physiological response to tissue injury or infection,
chronic inflammation is maladaptive and engenders a considerable amount of adverse pain …

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active
metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological …

Osteoarthritis (OA) can be defined as the result of pathological processes of various
etiologies leading to damage to the articular structures. Although the mechanism of …

Osteoarthritis (OA) is the most prevalent arthritis with an estimated global prevalence in
2020 of 22.9%(95% confidence interval [CI], 19.8%-26.1%) in persons over 40 years of age …

Abstract Purpose of Review To examine the effects and interactions between gut microbia
and chronic pain. Recent Findings The gut microbiome has been an area of interest in both …

Selective targeting to the tumor niche remains a major challenge in successful cancer
therapy. Somatostatin receptor 2 (SSTR2) is overexpressed in breast cancer cells thus …

Diabetes is part of metabolic diseases and is characterized by high blood sugar levels over
a prolonged period as result of an insulin‐deficient production or an inappropriate response …

Abstract Interleukin-6 (IL-6) signaling network has been implicated in oncogenic
transformations making it attractive target for the discovery of novel cancer therapeutics. In …

Necroptosis is suggested to have an important role in the pathogenesis of rhabdomyolysis
induced acute kidney injury (AKI). In this study, the renoprotective effect of diacerein on …